These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 16387106)
1. Gancyclovir prophylaxis in high risk patients. Campino A Transplant Proc; 2005 Dec; 37(10):4311-2. PubMed ID: 16387106 [TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease]. Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888 [TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L; Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546 [TBL] [Abstract][Full Text] [Related]
4. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients. Murray BM; Subramaniam S Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220 [TBL] [Abstract][Full Text] [Related]
5. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients. López-Medrano F; Rueda B; Lizasoain M; Juan RS; Folgueira D; Andrés A; Morales JM; Jiménez C; Meneu JC; Aguado JM Transpl Infect Dis; 2009 Oct; 11(5):400-4. PubMed ID: 19570139 [TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus infection in kidney transplant recipients: Evolution of approach through three eras. Boucher A; Lord H; Collette S; Morin M; Dandavino R Transplant Proc; 2006 Dec; 38(10):3506-8. PubMed ID: 17175316 [TBL] [Abstract][Full Text] [Related]
7. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408 [TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies. Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495 [TBL] [Abstract][Full Text] [Related]
13. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients. Stratta RJ; Alloway RR; Lo A; Hodge EE; Transplant Proc; 2004 May; 36(4):1082-3. PubMed ID: 15194376 [TBL] [Abstract][Full Text] [Related]
14. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors. Shah T; Lai WK; Mutimer D Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091 [TBL] [Abstract][Full Text] [Related]
15. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection. Dickenmann MJ; Kabulbayev K; Steiger J; Cathomas G; Reusser P; Tamm M Clin Microbiol Infect; 2004 Apr; 10(4):337-9. PubMed ID: 15059125 [TBL] [Abstract][Full Text] [Related]
16. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective? Goral S; Ynares C; Dummer S; Helderman JH Kidney Int Suppl; 1996 Dec; 57():S62-5. PubMed ID: 8941924 [TBL] [Abstract][Full Text] [Related]
17. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451 [TBL] [Abstract][Full Text] [Related]